Meta-analysis topic ideas in rheumatology and immunology

Rheumatology is dominated by a few well-trialled diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis) and a long list of rarer conditions such as vasculitis, systemic sclerosis and Sjogren's syndrome, where trials are small and often non-randomized. The drug trials are numerous, and many are funded by the manufacturers, who also fund many of the network meta-analyses.

That gives two kinds of opportunity: independent, carefully stratified analyses of crowded drug questions, and first syntheses for rare diseases, where a handful of cohorts and a few trials are all there is. The second is harder to power but easier to find a gap in.

Find a rheumatology and immunology topic that has not been done

SynthGap searches the published literature, checks each candidate against existing systematic reviews, and proposes topics with the primary studies behind them. Start on the Free plan: no card needed, and every run shows every topic it finds.

Where gaps tend to hide in rheumatology

Rare and overlapping diseases

Vasculitis, systemic sclerosis, myositis, Sjogren's syndrome and autoinflammatory diseases have few randomized trials. Systematic reviews of cohort studies and case series can still answer prevalence, prognosis and safety questions if their limits are stated.

Safety of biologics and small molecules

Infections, cardiovascular events, cancer and thrombosis after targeted therapies are reported as secondary outcomes in many trials and registries. Pooling adverse events needs careful handling of exposure time and rare events.

Tapering and withdrawal strategies

Whether disease control is kept when doses are reduced or stopped is tested in small trials with different definitions of remission and flare. Pooled estimates by drug class and by baseline disease activity are often missing.

Non-drug care

Exercise, diet, education and psychological therapy for fatigue and pain are studied across many rheumatic diseases, and reviews often mix them in ways that hide which component helps.

Paediatric and pregnancy-related questions

Juvenile arthritis and the management of rheumatic disease around pregnancy and breastfeeding rest on small studies, so an up-to-date synthesis can be valuable.

Outcomes and effect measures that pool well in rheumatology

ACR20, ACR50 and ACR70 response, and EULAR response criteria: risk ratios, defined at a stated week, with the placebo response reported.
Disease activity scores (DAS28, ASDAS, BASDAI, SLEDAI): mean differences when the same score is used, standardized mean differences only if scores differ. DAS28 behaves differently depending on whether C-reactive protein or the erythrocyte sedimentation rate is used.
Remission and low disease activity: risk ratios, with the definition (Boolean, index-based, ACR/EULAR) written out.
Radiographic progression (modified total Sharp score): mean difference, with attention to missing data from patients who left early.
Serious infections and other adverse events: risk ratios or odds ratios with a method suited to rare events, and exposure-adjusted rates when the data allow it.

Common traps in rheumatology reviews

Treating a response after a few weeks in a placebo-controlled phase and a response after a year of open-label extension as the same outcome.
Indirect comparisons between drugs from trials with very different populations, for example patients new to biologics and patients who had failed several.
Counting an extension study and its parent trial as separate studies.
Using patient-reported outcomes from open-label designs without noting the risk of bias.
Pooling lupus trials that define response with different indices (SRI-4, BICLA).

Check before you commit

Before committing months to a topic, check that nobody has beaten you to it. Search PubMed with its systematic review filter, the Cochrane Library (the Cochrane Musculoskeletal group covers rheumatoid arthritis and related conditions), PROSPERO for registered reviews, and Epistemonikos. For crowded drug questions, expect several network meta-analyses and decide what yours adds. Step-by-step guide.

Starting points to try in SynthGap

These are areas to explore, not claims that they are open. Some may already be well covered, and finding that out quickly is the point.

Tapering biologics in axial spondyloarthritis after sustained remission
Pregnancy outcomes in women with systemic sclerosis or vasculitis
Exercise and fatigue in systemic lupus erythematosus

Questions

How do I check whether a rheumatology meta-analysis already exists?

Search PubMed with the systematic review filter, the Cochrane Library, PROSPERO and Epistemonikos. For biologics, check the date of the last search, because new trials appear every year.

Should I do a network meta-analysis of biologics?

Many already exist, often with industry links. A new one needs a clear reason: a new drug class, a new outcome, or a population that earlier networks left out. Otherwise a focused pairwise analysis may be more useful.

Can I pool studies of rare rheumatic diseases?

Yes, if the question is about prevalence, outcomes or safety, and you use methods for proportions or rare events. Be explicit that the evidence is mostly observational and that heterogeneity will be high.

Other specialties

This page is general methodological guidance, not medical advice, and it does not list specific unreviewed topics. SynthGap's suggestions are AI-generated from the published literature, so verify them before registering a protocol.